Evidence map›Paper›PMID 28395671›Full record

Observational studyJournal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance2017

Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab: a prospective observational study.

Ashita Barthur, Christine Brezden-Masley, Kim A Connelly, Vinita Dhir, Kelvin K W Chan, Rashida Haq, Anish Kirpalani, Joseph J Barfett, Laura Jimenez-Juan, Gauri R Karur and 2 more

Registry-linked trialOpen access · goldAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01022086 (Assessment of Cardiotoxicity by Cardiac MRI Versus MUGA Scans in Breast Cancer Patients Receiving Trastuzumab), which is not on this map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01022086 unknown statusnot on this map

Assessment of Cardiotoxicity by Cardiac MRI Versus MUGA Scans in Breast Cancer Patients Receiving Trastuzumab: A Double-Blinded Prospective Observational Pilot Study

TypeobservationalSponsorUnity Health TorontoRan2009 to 2019Enrolled50ConditionsStage I-IV Breast Cancer (Neo-adjuvant, Adjuvant, Locally Advanced and Metastatic)ArmsCardiac MRI, Biomarker Testing
3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. How to Use Multimodality Imaging in Cardio-Oncology.Journal of cardiovascular development and disease · 2026
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Ashita BarthurDepartment of Medical Imaging, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
Christine Brezden-MasleyDivision of Hematology/Oncology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
Kim A ConnellyKeenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
Vinita DhirDivision of Hematology/Oncology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
Kelvin K W ChanSunnybrook Health Sciences Centre, University of Toronto, Cancer Care Ontario, Canadian Center for Applied Research in Cancer Control, Toronto, ON, Canada.
Rashida HaqDivision of Hematology/Oncology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
Anish KirpalaniDepartment of Medical Imaging, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
Joseph J BarfettDepartment of Medical Imaging, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
Laura Jimenez-JuanDepartment of Medical Imaging, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
Gauri R KarurDepartment of Medical Imaging, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
Djeven P DevaDepartment of Medical Imaging, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada. devad@smh.ca.
Andrew T YanKeenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada. yana@smh.ca.
St. Michael's Hospital · CAUniversity of Toronto · CAHealth Sciences Centre · CASunnybrook Health Science Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere are limited data on the effects of trastuzumab on the right ventricle (RV). Therefore, we sought to evaluate the temporal changes in right ventricular (RV) structure and function as measured by cardiovascular magnetic resonance (CMR), and their relationship with left ventricular (LV) structure and function in breast cancer patients treated with trastuzumab.

methodsProspective, longitudinal, observational study involving 41 women with HER2+ breast cancer who underwent serial CMR at baseline, 6, 12, and 18 months after initiation of trastuzumab. A single blinded observer measured RV parameters on de-identified CMRs in a random order. Linear mixed models were used to investigate temporal changes in RV parameters.

resultsOf the 41 women (age 52 ± 11 years), only one patient experienced trastuzumab-induced cardiotoxicity. Compared to baseline, there were small but significant increases in the RV end-diastolic volume at 6 months (p = 0.002) and RV end-systolic volume at 6 and 12 months (p < 0.001 for both), but not at 18 months (p = 0.82 and 0.13 respectively). RV ejection fraction (RVEF), when compared to baseline (58.3%, 95% CI 57.1-59.5%), showed corresponding decreases at 6 months (53.9%, 95% CI 52.5-55.4%, p < 0.001) and 12 months (55%, 95% CI 53.8-56.2%, p < 0.001) that recovered at 18 months (56.6%, 95% CI 55.1-58.0%, p = 0.08). Although the temporal pattern of changes in LVEF and RVEF were similar, there was no significant correlation between RVEF and LVEF at baseline (r = 0.29, p = 0.07) or between their changes at 6 months (r = 0.24, p = 0.17).

conclusionIn patients receiving trastuzumab without overt cardiotoxicity, there is a subtle but significant deleterious effect on RV structure and function that recover at 18 months, which can be detected by CMR. Furthermore, monitoring of LVEF alone may not be sufficient in detecting early RV injury. These novel findings provide further support for CMR in monitoring early cardiotoxicity.

trial registrationClinicalTrials.gov Identifier: NCT01022086 . Date of registration: November 27, 2009.

Indexed as

Magnetic Resonance Imaging, CineAdultAnalysis of VarianceAntineoplastic Agents, ImmunologicalBreast NeoplasmsCardiotoxicityEarly DiagnosisFemaleHeart VentriclesHumansLinear ModelsLongitudinal StudiesMiddle AgedOntarioPredictive Value of TestsProspective StudiesAntineoplastic Agents, ImmunologicalTrastuzumabCardiotoxicityCardiovascular magnetic resonanceRight ventricleTrastuzumab

Identifiers

PMID28395671
PMCPMC5387372
OpenAlexW2607112370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.